The MicroRNA Detection (MiDe) Study
Research type
Research Study
Full title
Analysis of a microRNA-based signature of breast and ovarian cancer in women with familial cancer
IRAS ID
296830
Contact name
Usha Menon
Contact email
Sponsor organisation
UCL
Clinicaltrials.gov Identifier
Z6364106/2021/05/52, UCL DP Ref
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
Detection of ovarian cancer at an early stage greatly improves the survival rate. Currently, there are no screening or early detection tests available for ovarian cancer, which has an extremely high mortality rate. Biomarkers with sufficient sensitivity for early ovarian cancer screening is crucial. \n\nThe MiDe Study (MicroRNA Detection Study) is working to develop a biomarker signature for early ovarian cancer detection utilising a novel class of molecules, called microRNAs (miRNA). In this work, we propose to utilise serially serum samples previously collected during UKFOCSS (United Kingdom Familial Ovarian Screening Study) to look at the miRNA network, consisting of 14 validated molecules. The research project under the current application aims to investigate whether miRNA biomarkers in serum can detect those individuals who have developed breast and ovarian cancer. This work aims to contribute to the discovery of novel biomarkers that might be able to detect earlier a cancer diagnosis and thus in the future potentially contribute to a non-invasive early cancer detection test that can be widely implemented. \n
REC name
North of Scotland Research Ethics Committee 2
REC reference
21/NS/0082
Date of REC Opinion
24 Jun 2021
REC opinion
Favourable Opinion